Pharmacogenetics to Avoid Adverse Drug Reactions

Abstract

Gregorio Mara ñ ón. His current lines of research are related to the study of drug response and toxicity in multiple pathologies (cancer, neurology, immunology, psychiatry). He is the author of more than 90 peer-reviewed articles included in the journal citation report. Currently, Dr. L ópez-Fernández is leading studies whose objectives are to identify genetic variants associated with responses to biologic therapy in children with inflammatory bowel disease, to develop a simple and inexpensive pharmacogenetic test to be implemented in countries with limited resources, and to identify genomic biomarkers associated with opioid abuse and dual pathology.vii Preface to "Pharmacogenetics to Avoid Adverse Drug Reactions"Although a cure is the main goal of a treatment, serious adverse reactions associated with treatments are a major problem in clinical practice and cost healthcare systems a lot of money. These adverse reactions limit the success of drugs and can even lead to the death of patients. Identifying the DNA variants associated with adverse drug reactions can help to personalize medicine and sustain healthcare systems. This book focuses on the following topics: the identification of DNA variants associated with adverse drug reactions and their clinical application. It contains seven original papers and four reviews that will spread the knowledge on these critical matters. The pharmacogenetic works presented in this Special Issue can be classified into three major areas: cardiovascular, cancer, and the nervous system. This book is aimed at cardiologists, oncologists, neurologists, psychiatrists, geneticists, molecular biologists, and hospital pharmacists and other healthcare personnel.I would like to thank the staff at the Laboratory of Pharmacogenetics of the Hospital Gregorio Mara ñ ón for their support, and the patients who have participated in all the research studies shown here.